# Faricimab for Chronic Central Serous Chorioretinopathy: A Randomized Sham-Controlled Trial

> **NCT07681167** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Singapore National Eye Centre** · enrollment: 50 (estimated)

## Conditions studied

- Central Serous Chorioretinopathy (CSC)

## Interventions

- **DRUG:** Faricimab
- **DRUG:** Sham

## Key facts

- **NCT ID:** NCT07681167
- **Lead sponsor:** Singapore National Eye Centre
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-12
- **Primary completion:** 2029-08
- **Final completion:** 2029-08
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2026-07-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07681167

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07681167, "Faricimab for Chronic Central Serous Chorioretinopathy: A Randomized Sham-Controlled Trial". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07681167. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*